Lineage Cell Therapeutics (LCTX) announced the initiation of a new islet cell transplant program in Type 1 Diabetes. Specifically, the company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishing a production modality that can support the entire production process in a dynamic culturing system.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges
- Buy Recommendation for Lineage Cell Therapeutics Driven by Strategic Partnerships and Financial Positioning
- Strategic Partnerships and Promising Trial Results Bolster Buy Rating for Lineage Cell Therapeutics
- Lineage Therap Partners with WDI for Hearing Loss Research
- Lineage Cell Therapeutics enters research pact with William Demant Invest